%20-%20http://www.bohemiancoding.com/sketch%20--%3e%3ctitle%3eIcon/Menu%3c/title%3e%3cdesc%3eCreated%20with%20Sketch.%3c/desc%3e%3cdefs%3e%3cpolygon%20id='path-1'%20points='0.0005%200.646%2022.386%200.646%2022.386%203.1455%200.0005%203.1455'%3e%3c/polygon%3e%3cpolygon%20id='path-3'%20points='0.0005%200.9341%2022.386%200.9341%2022.386%203.4341%200.0005%203.4341'%3e%3c/polygon%3e%3cpolygon%20id='path-5'%20points='0.0005%200.5%2022.386%200.5%2022.386%203%200.0005%203'%3e%3c/polygon%3e%3c/defs%3e%3cg%20id='Symbols'%20stroke='none'%20stroke-width='1'%20fill='none'%20fill-rule='evenodd'%3e%3cg%20id='Icon/Menu'%3e%3cg%20id='Group-10-Copy'%20transform='translate(3.800000,%205.300000)'%3e%3cg%20id='Group-3'%20transform='translate(0.000000,%200.354500)'%3e%3cmask%20id='mask-2'%20fill='white'%3e%3cuse%20xlink:href='%23path-1'%3e%3c/use%3e%3c/mask%3e%3cg%20id='Clip-2'%3e%3c/g%3e%3cpath%20d='M22.3865,2.6455%20C22.3865,2.9205%2022.1615,3.1455%2021.8865,3.1455%20L0.5005,3.1455%20C0.2245,3.1455%200.0005,2.9205%200.0005,2.6455%20L0.0005,1.1455%20C0.0005,0.8705%200.2245,0.6455%200.5005,0.6455%20L21.8865,0.6455%20C22.1615,0.6455%2022.3865,0.8705%2022.3865,1.1455%20L22.3865,2.6455%20Z'%20id='Fill-1'%20fill='%23FFFFFF'%20mask='url(%23mask-2)'%3e%3c/path%3e%3c/g%3e%3cg%20id='Group-6'%20transform='translate(0.000000,%207.354500)'%3e%3cmask%20id='mask-4'%20fill='white'%3e%3cuse%20xlink:href='%23path-3'%3e%3c/use%3e%3c/mask%3e%3cg%20id='Clip-5'%3e%3c/g%3e%3cpath%20d='M22.3865,2.9341%20C22.3865,3.2091%2022.1615,3.4341%2021.8865,3.4341%20L0.5005,3.4341%20C0.2245,3.4341%200.0005,3.2091%200.0005,2.9341%20L0.0005,1.4341%20C0.0005,1.1591%200.2245,0.9341%200.5005,0.9341%20L21.8865,0.9341%20C22.1615,0.9341%2022.3865,1.1591%2022.3865,1.4341%20L22.3865,2.9341%20Z'%20id='Fill-4'%20fill='%23FFFFFF'%20mask='url(%23mask-4)'%3e%3c/path%3e%3c/g%3e%3cg%20id='Group-9'%20transform='translate(0.000000,%2015.354500)'%3e%3cmask%20id='mask-6'%20fill='white'%3e%3cuse%20xlink:href='%23path-5'%3e%3c/use%3e%3c/mask%3e%3cg%20id='Clip-8'%3e%3c/g%3e%3cpath%20d='M22.3865,2.5%20C22.3865,2.775%2022.1615,3%2021.8865,3%20L0.5005,3%20C0.2245,3%200.0005,2.775%200.0005,2.5%20L0.0005,1%20C0.0005,0.725%200.2245,0.5%200.5005,0.5%20L21.8865,0.5%20C22.1615,0.5%2022.3865,0.725%2022.3865,1%20L22.3865,2.5%20Z'%20id='Fill-7'%20fill='%23FFFFFF'%20mask='url(%23mask-6)'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23fff'%20fill-rule='nonzero'%3e%3cg%20id='icon/fold'%20transform='translate(240.000000,%20272.000000)'%3e%3cpath%20d='M11.5,2.3%20C6.4216,2.3%202.3,6.4216%202.3,11.5%20C2.3,16.5784%206.4216,20.7%2011.5,20.7%20C16.5784,20.7%2020.7,16.5784%2020.7,11.5%20C20.7,6.4216%2016.5784,2.3%2011.5,2.3%20Z%20M10.58,18.7956%20C6.946,18.3448%204.14,15.2536%204.14,11.5%20C4.14,10.9296%204.2136,10.3868%204.3332,9.8532%20L8.74,14.26%20L8.74,15.18%20C8.74,16.192%209.568,17.02%2010.58,17.02%20L10.58,18.7956%20Z%20M16.928,16.4588%20C16.6888,15.7136%2016.008,15.18%2015.18,15.18%20L14.26,15.18%20L14.26,12.42%20C14.26,11.914%2013.846,11.5%2013.34,11.5%20L7.82,11.5%20L7.82,9.66%20L9.66,9.66%20C10.166,9.66%2010.58,9.246%2010.58,8.74%20L10.58,6.9%20L12.42,6.9%20C13.432,6.9%2014.26,6.072%2014.26,5.06%20L14.26,4.6828%20C16.9556,5.7776%2018.86,8.418%2018.86,11.5%20C18.86,13.4136%2018.124,15.1524%2016.928,16.4588%20Z'%20id='形状'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
媒體文章
了解權威媒體如何報道藥明康德賦能醫藥健康產業的專題文章、訪談，從第三方視角，展現藥明康德的CRDMO能力與對全球生命科學創新的貢獻。
了解權威媒體如何報道藥明康德賦能醫藥健康產業的專題文章、訪談，從第三方視角，展現藥明康德的CRDMO能力與對全球生命科學創新的貢獻。
筛选
全部年份
2026/09/21
媒體聲音|當創新藥越來越複雜，真正拖慢項目的是什麼？
在這場深度對話中，陳珂博士回顧了近年來行業的深刻變革，剖析了複雜藥物分子背後的生產挑戰、全球供應網絡需要怎樣的抗風險能力，並展望了未來五年原料藥生產的演進方向。
閲讀更多2026/08/20
媒體聲音 | 藥明康德Co-CEO楊青博士：如何打造更具韌性的生物醫藥創新體系
近日，藥明康德聯席首席執行官楊青博士在行業媒體Fierce Biotech上圍繞這一話題分享了他的思考：生物醫藥產業的脆弱性由何而來？如何能讓創新研發保持高效？展望未來，生物醫藥產業又需要做好哪些準備？楊青博士指出，唯有打造一個更具韌性的創新體系，才能「千磨萬擊還堅勁，任爾東西南北風」，在複雜性和不確定中找尋到錨點，持續加速創新落地，造福病患。
閲讀更多2026/05/18
媒体声音 | 对话联席首席执行官陈民章博士，药明康德全球产能布局按下“加速键”
日前，行業媒體Pharma Manufacturing主編 Greg Slabodkin 訪問了公司聯席執行長陳民章博士，圍繞全球產能建設、新分子能力佈局及未來發展戰略等話題展開深入交流。
閲讀更多2026/05/05
媒體聲音 | 從「做實驗」到「做決策」：一體化平台如何重塑早期新藥研發
為了幫助全球創新者更好地應對這一挑戰，藥明康德依托獨特的一體化CRDMO平台，將研究、開發與生產能力整合在一個全球化的體系之中，助力合作夥伴優化研發流程、提升專案效率。憑藉二十餘年的行業積累，藥明康德持續支持客戶加快專案推進，推動創新療法更早惠及病患。
閲讀更多2026/04/21
媒體聲音｜藥明康德一體化CRDMO如何讓創新療法更快造福病患
近日，藥明康德高級副總裁、寡核苷酸和多肽事業部及化學業務平台商務運營部負責人盧羽女士接受行業媒體Fierce Biotech採訪，分享了藥明康德的一體化能力和全球網絡協同，如何以「藥明速度」，加速推動客戶新一代創新療法的開發。
閲讀更多